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ABSTRACT
Patients with coexisting medical problems may suffer increased toxicity and reduced quality of life after autolo-
gous hematopoietic stem cell transplantation (HSCT). The benefit of high-dose therapy for some patients with
multiple myeloma (MM) is debatable. Decision tools that aid in identifying those patients with MMmost suited
for autologous HSCT may avoid the risk of excess toxicity. An objective assessment of comorbidities was
performed in 126 patients with MM undergoing autologous HSCT using the Charlson comorbidity index
(CCI), the hematopoietic cell transplantation comorbidity index (HCT-CI), and a modified pretransplantation
assessment ofmortality (mPAM) to determine the strength of association with increased transplantation-related
toxicity and increased length of hospital stay (LOS). Any comorbidity scored using the CCI or HCT-CI (score.
0) was associated with an increased number of organ systems with serious toxicity (at least grade 2 toxicity using
the Seattle criteria), an increased total sum of toxicity grades for all organs, and prolonged LOS. An mPAM
score$ 24 was associated with increased LOS.When considering autologous HSCT for a patient with MM, as-
sessment of comorbidities using the CCI or HCT-CI may assist in predicting the risk of transplantation-related
toxicity as an adjunct to physician judgment and patient preference.
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Pretransplantation assessment of comorbidities is an
important aspect of determining a patient’s ‘‘fitness’’ for
blood and marrow transplantation. Objective scoring
using comorbidity scales and formal pretransplantation
assessments have been reported only recently for pa-
tients undergoing hematopoietic stem cell transplanta-
tion (HSCT). Formal scoring systems for measuring
comorbidity have proven useful in predicting increased
mortality after allogeneic HSCT [1,2]. Although not
clearly demonstrated in previous reports, comorbidities
also may increase the risk of nonfatal regimen-relatedtoxicity that can compromise performance status after
the transplantation. Balancing regimen-induced toxicity
with the benefits of autologous HSCT is particularly
important for older patients with hematologic malig-
nancies, such as multiple myeloma (MM).
Several studies have demonstrated improved
survival in younger patients with MM undergoing au-
tologous HSCT [3,4]; however, patients of advanced
age or with significant comorbidities often are
excluded because of the perceived risk of excessive tox-
icity. Studies of older patients have been less clear re-
garding a survival advantage with transplantation [5],1039
1040 L. Labonte et al.and no general consensus has emerged regarding clear
exclusion criteria. Decision tools that aid in the selec-
tion of patients with MM most suited for autologous
HSCT are needed to provide a better rationale for eval-
uating the risk of transplantation-related morbidity in
older patients with coexisting medical problems and
to better define those patients most likely to benefit.
In the present study, we addressed the association
of pretransplantation comorbidity scores and trans-
plantation-related toxicity in patients with MM. Three
different scoring systems were compared: the Charlson
comorbidity index (CCI) [6], the hematopoietic cell
transplantation comorbidity index (HCT-CI) [1],
and a modified pretransplantation assessment of mor-
tality (mPAM) [2]. Herein we report the association of
medical comorbidity as measured by the CCI and
HCT-CI scoring systems with increased toxicity after
autologous HSCT in patients with MM.
PATIENTS AND METHODS
Patients
All patients undergoing autologous HSCT at The
Ottawa Hospital between January 2000 and December
2005 for MM and who provided informed consent for
the use of medical information for research purposes
were included in the analysis. Toxicity data related to
a second or subsequent transplantation in any patient
were excluded. Patient data and clinical information
related to either comorbidity assessment or transplan-
tation-related toxicity outcomes were retrieved from
The Ottawa Hospital’s blood and marrow transplant
registry. In addition, hospital medical records were re-
viewed for all patients. All patients except 1 patient
with concomitant low-grade lymphoma received
melphalan 200 mg/m2 as a conditioning therapy
before reinfusion of peripheral blood stem cells. The
peripheral blood stem cells were collected in a mean
of 1.3 6 0.5 apheresis collections (median, 1.0; range,
1-3), and the patients were reinfused with 7.3 6 4.7 
106 CD341 cells per kg. Five patients underwent a sec-
ond autologous HSCT. Toxicity data and comorbidity
assessments were performed with regard to the first
transplantation in all cases.
Pretransplantation Comorbidity Assessment
Table 1 compares the scoring systems for the 3 co-
morbidity assessment scales used in this study. The
CCI and HCT-CI scoring systems are similar, but
the HCT-CI incorporates a greater number of comor-
bidities and assigns more points for certain medical
problems. The mPAM incorporates fewer comorbid-
ities, includes age and disease status as important
factors, and assigns points for donor type and condi-
tioning regimen. Details of these scoring systems
have been published previously [1,2,6]. Clinical data
gathered at the time of consultation by the transplan-tation team or from testing performed before trans-
plantation were used to generate scores for each
patient according to the criteria of the CCI, HCT-
CI, and mPAM systems. Body mass index could not
be calculated for all patients, because data were not
available in some cases. It was therefore excluded
from the analysis for all patients, affecting scores for
the HCT-CI only. In all instances, if data concerning
a particular medical comorbidity were not available for
an individual, then it was assumed that no abnormality
was present, and the scores were applied accordingly.
Toxicity Endpoints
The primary endpoint was the number of organs
with serious toxicity (organ toxicity grade$ 2) accord-
ing to the Seattle criteria (grades 0-4). Details of this
toxicity scoring system have been published previously
[7]. In addition, secondary measures of toxicity ana-
lyzed in the present study were the total sum of toxicity
grades for all 8 organ systems captured by the Seattle
criteria, stratified into high toxicity ($ 2 total toxicity
grades) and low toxicity (\2 total toxicity grades), and
the length of hospital stay (LOS) after reinfusion of the
stem cell graft, stratified according to the median LOS
into short (\18 days) and long ($ 18 days). Nonre-
lapse mortality before day 100 and admission to an in-
tensive care unit (ICU) occurred in only a small
number of patients and were not used as toxicity end-
points in this study.
Statistical Methods
Our null hypothesis was that none of the scoring
systems for pretransplantation comorbidity assess-
ment would be associated with increased toxicity after
Table 1. Pretransplantation Assessment Scoring Systems
Scoring System
Comorbidity CCI HCT-CI mPAM
Arrythmia - 1 -
Cardiac disease 1 1 -
Inflammatory bowel disease - 1 -
Diabetes 1 1 -
Cerebrovascular disease 1 1 -
Psychiatric disease - 1 -
Hepatic disease, mild 1 1 2
Obesity - 1 -
Infection - 1 -
Rheumatologic disease 1 2 -
Peptic ulcer disease 1 2 -
Renal disease, moderate/severe 2 2 8
Previous solid tumor 2 3 -
Valvular heart disease - 3 -
Pulmonary disease, disease 1 3 3-6
Hepatic disease, moderate/severe 3 3 2
Age - - 1-5
Donor type - - 1-4
Disease risk - - 1-12
Conditioning regimen - - 1-9
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Organ Grade 1 Grade 2 Grade 3
Bladder Asymptomatic macroscopic
hematuria after 2 days from
chemotherapy
Macroscopic hematuria after
7 days from chemotherapy
or symptomatic
Hemorrhagic cystitis requiring
intervention
Renal Increased creatinine\ 2
baseline
Increased creatinine . 2
baseline
Requires dialysis
Gastrointestinal Noninfectious watery
diarrhea
500-2000 mL/day
Noninfectious watery
diarrhea .2000 mL/day or
hemorrhagic stools or subileus
Ileus requiring nasogastric suction
and/or surgery or hemorrhagic
stools requiring transfusion
Hepatic Bilirubin .34 and\ 102 g/L or
weight gain 2.5%-5.0% or
AST .2 and\5 baseline
Bilirubin .102 and\ 340 g/L or
weight gain . 5.0% or ascites
or AST . 5 baseline
Bilirubin . 340 g/L or
encephalopathyor ascites causing
respiratory compromise
Oral Mucositis Pain and/or ulceration not
requiring continuous
systemic narcotic
Pain and/or ulceration requiring
continuous systemic narcotic
Pain and/or ulceration requiring
preventive intubation or
aspiration pneumonia
Cardiovascular Asymptomatic heart
enlargement
of chest x-ray or
asymptomatic
ECG changes
Heart failure responsive to
diuretics or ECG changes
requiring medical intervention
Heart failure unresponsive to
medical intervention or severe
ECG changes unresponsive to
medical intervention
Nervous
System
Somnolence but
easily rousable
Somnolence with confusion, or
other new central nervous
system symptoms
Seizures or coma not otherwise
explained
Pulmonary Dypnea without chest x-ray
changes or isolated infiltrate
or mild interstitial changes
Moderate infiltrates or interstitial
changes or 10% decrease
in partial pressure of oxygen
Requires .50% O2 or mechanical
intubation
AST, aspartate aminotransferase; ECG, electrocardiogram.autologous HSCT for MM. All analyses were
performed using SPSS for Windows, version 15.0.
Scores for the CCI, HCT-CI, and mPAM were used
as predictors for logistic regression using increased
number of organ systems with $ grade 2 toxicity,
LOS . 18 days, and increased total sum of toxicity
grades for all organs as outcome variables. The contin-
uous variables were mPAM score and LOS. The mean,
median, and range were considered before categoriza-
tion into dichotomous variables was done. The CCI
score, HCT-CI score, increased number of organ
systems with $ grade 2 toxicity, and increased total
sum of toxicity grades for all organs were considered
ordinal categorical variables, and all possible combina-
tions of the variables were developed and applied to
logistic regression before the dichotomous categories
with the best fit in terms of odds ratio (OR), 95%
confidence interval (CI), and P value were selected.
Binary logistic regression was performed for the
analysis of all events (with 216 events analyzed using
3 independent variables, or 72:1), in accordance with
standard methods [8,9]. Univariate logistic regression
was performed on the predictor and outcome
variables. All values are reported as mean6 1 standard
deviation (SD).
RESULTS
The entire cohort of 126 patients underwent autol-
ogous HSCT to treat MM. Patient characteristics are
presented in Table 3. Disease stage was assigned usingthe Salmon-Durie classification system [10] (see Table
2). Insufficient data were available to allow us to assign
the International Working Group staging classification
[11] for all patients. Historical information regarding
preexisting known medical problems was available for
all patients. Pulmonary function tests were performed
in 51% of the patients, and objective cardiac function
Table 3. Patient Characteristics
Patient Characteristic n 5 126
Age, years, mean (range) 56 (33-69)
Male/female, n 72/54
Stage at diagnosis (Salmon-Durie
classification), n (%)
Stage 1 9 (7)
Stage 2 37 (29)
Stage 3 75 (60)
Not available 5 (4)
Days from diagnosis to first transplantation,
mean (SD)
409 (650)
Graft CD341 cells  106/kg, n, mean ± SD 7.3 ± 4.7
Days to neutrophil engraftment, mean ± SD 12.5 ± 3.9
Days to platelet engraftment, mean ± SD 13.8 ± 6.4
Number of organs with toxicity grade $ 1,
mean ± SD
1.4 ± 1.2
Number of organs with toxicity grade $ 2,
mean ± SD
0.4 ± 0.8
Total LOS, days, mean (range) 18 (10-80)
Patients requiring ICU admission, n (%) 3 (2.4)
Nonrelapse mortality at day 1100, n (%) 1 (0.8)
Pretransplantation CCI score, mean ± SD 0.6 ± 0.8
Pretransplantation HCT-CI score, mean ± SD 1.0 ± 1.3
Pretransplantation mPAM score, mean ± SD 23 ± 3.5
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transplantation. Alanine aminotransferase (ALT) mea-
surements were not available before transplantation in
10 patients, and pretransplantation serum creatinine
values could not be obtained in 3 patients.
Within the total cohort, the mean number of or-
gans with at least grade 1 toxicity was 1.46 1.2. A total
of 27 patients (21%) had no toxicity in any organ sys-
tem, 49 (39%) had toxicity in a single organ system, 31
(25%) had involvement of 2 organ systems, 8 (6.3%)
had involvement of 3 organ systems, and 10 (7.9%)
had involvement of 4 or more organ systems. Oral mu-
cositis, was the most common toxicity and occurred in
88 patients (70%), whereas gastrointestinal toxicity,
the second most common organ system toxicity, oc-
curred in 34 patients (27%). Pulmonary, renal, and
cardiac toxicity occurred in 14 (11%), 14 (11%), and
13 patients (10%), respectively. Central nervous sys-
tem, hepatic, and bladder toxicity were less common,
occurring in only 9 (7%), 5 (4%), and 2 patients
(1.6%), respectively.
Thirty-one patients (25%) had toxicity of at least
grade 2 in 1 or more organ systems, including 22
(17%) with 1 organ system, 5 (4%) with 2 organ
systems, 2 (1.6%) with 3 organ systems, and 2 (1.6%)
with 4 or more organ systems severely affected. Severe
mucositis (16 patients; 13%), cardiac toxicity (8 pa-
tients; 6%), gastrointestinal toxicity (6 patients; 5%),
and renal impairment (6 patients; 5%) were the most
frequent toxicities with toxicity scores $ 2 (see
Figure 1).
The mean LOS after reinfusion of hematopoietic
stem cells was 18 days (range, 10-80 days). Nonrelapse
mortality occurred in only 2 patients before day 100
after transplantation; thus, this could not be used as
a measure of toxicity in our cohort. Furthermore, ad-
mission to the ICU occurred in only 3 cases, and all
3 of those patients were alive at last follow-up. Given
the low incidence of ICU admission, this also could
not be used as a means of discerning differences in
overall toxicity in our cohort.
Charlson Comorbidity Index
Of the total cohort of 126 patients, 68 (54%)
scored no points on the CCI scale, 47 (37%) scored
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Figure 1. Percentage of patients with serious organ toxicity (at least
grade 2) in each of 8 organ systems according to the Seattle criteria.1 point, 5 (4%) scored 2 points, 3 (2.3%) scored 3
points, and 7 (5.6%) scored$ 4 points. The most com-
mon comorbidities were lung disease, liver abnormal-
ities, and diabetes, with 36 patients (29%), 21 patients
(17%), and 8 patients (6.3%) scoring at least 1 point on
the CCI for these, respectively (see Figure 2). Only 2
patients (1.6%) scored points in the categories of
cardiovascular and renal comorbidities.
Our cohort was divided into low CCI score (0; n5
68) and high CCI score ($ 1; n5 58). Logistic regres-
sion revealed an important trend toward an increased
number of organs with serious toxicity in the group
with a high CCI comorbidity score (OR 5 2.27; 95%
CI 5 0.99-5.22; P 5 .053). Comorbidity as measured
by the CCI scale was significantly correlated with
a high overall sum of toxicity grades (n 5 55 with
a sum $ 2) (OR 5 2.19; 95% CI 5 1.06-4.49; P 5
.033) and with prolonged LOS beyond 18 days (OR
4.05; 95% CI5 1.76-9.28; P5 .001). Results of logis-
tic regression analysis are summarized in Table 4.
Furthermore, dividing the cohort into 2 groups,
a low CCI group with 0 or 1 point (n 5 115) and
a high CCI group with $ 2 points (n 5 11), led to
a significant correlation between high CCI score
and the primary endpoint of increased number of
organ systems with severe toxicity (OR 5 4.32; 95%
CI 5 1.12-15.3; P 5 .024) and a significant trend to-
ward increased total sum of organ toxicity grades
(OR 5 0.96-15.1; P 5 .058) and increased total LOS
(OR 5 0.96-11.8; P 5 .059).
Hematopoietic Cell Transplantation Comorbidity
Index
Using the HCT-CI assessment of comorbidity led
to a similar association between comorbidity and tox-
icity in our patients. A total of 66 patients (52%) had
a comorbidity score of 0 according to the HCT-CI,
21 (17%) had a score of 1, 17 (13%) had a score of 2,
15 (12%) had a score of 3, and 7 (5.5%) had a score
of $ 4. The distribution of patients with lung disease,
hepatic abnormalities, diabetes, cardiac disease, and
renal impairment was identical to that for the CCI
(see Figure 2). In addition, 4 patients had comorbidity
scores assigned for other diseases not captured by the
CCI (3 patients with psychiatric illness and 1 patient
with malaria).
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Figure 2. Percentage of patients with points for specific comorbid-
ities using either the CCI or HCT-CI.
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(score of 0; n 5 66) and high HCT-CI score (score of
$ 1; n 5 60). Logistic regression revealed a significant
correlation between high HCT-CI score and an in-
creased number of organs with severe toxicity (OR 5
2.50; 95% CI 5 1.08-5.80; P 5 .033). High HCT-CI
score also was correlated significantly with our second-
ary toxicity outcomes of increased sum total of toxicity
grades for all organ systems (n 5 55 with a sum $ 2)
(OR 5 2.22; 95% CI 5 1.08-4.55; P 5 .03) and
prolonged LOS beyond 18 days (OR 5.34; 95% CI 5
2.24-12.75; P\ .001) (Table 4).
Modified Pretransplantation Assessment of
Mortality
None of the patients in the present study scored
any points according to the mPAM scoring system
with regard to donor type, because all of the patients
underwent autologous HSCT. Furthermore, all of
the patients had a similar score for disease risk. All
but 1 patient also received the identical conditioning
regimen of high-dose (200 mg/m2) melphalan and
had the same score; however, 1 patient was treated
with melphalan, etoposide, and total body irradiation
(500 cGy in a single fraction) for concomitant low-
grade lymphoproliferative disease and scored 8 points
instead of 4 for the conditioning regimen due to the in-
clusion of total body irradiation. Many of the patients
(103; 82%) scored additional points for increased age
(62 patients with a score of 3 for age 50-60 years and
41 patients with a score of 5 for age . 60 years).
Thirty-five patients scored additional points for pul-
monary function abnormalities (17 with abnormal
forced expiratory volume in 1 minute and 18 with a de-
creased lung CO2 diffusion capacity), 11 patients
scored additional points for elevated serum creatinine
level, and 6 patients scored additional points for abnor-
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Figure 3. Distribution of patients with specific mPAM scores.mal ALT values. Figure 3 shows the distribution of
mPAM scores in our patients.
Logistic regression revealed no significant correla-
tion between increased mPAM score and the number
of organs with severe toxicity. Analysis of the data
failed to identify any specific cutoff value for mPAM
scores that stratified the cohort into 2 groups that dif-
fered in terms of our primary toxicity endpoint; how-
ever, when the cohort was divided into low mPAM
score (score # 23; n 5 83) and high mPAM score
(score $ 24; n 5 43), higher mPAM scores were asso-
ciated with prolonged LOS beyond 18 days (OR 5
3.03; 95% CI 5 1.35-12.75; P \ .001). Using the
same cutoff for low and high mPAM scores revealed
a possible trend toward an increased number of organs
with severe toxicity (OR5 1.87; 95% CI5 0.82-4.30;
P5 .14) and a trend toward an increased sum of toxic-
ity grades (OR5 1.93; 95% CI5 0.91-4.09; P5 .087).
Results of logistic regression analysis are summarized
in Table 4.
DISCUSSION
The present study has demonstrated the utility of
the CCI and HCT-CI comorbidity scales in identify-
ing patients at risk for increased toxicity after autolo-
gous HSCT for MM. Any comorbidity captured by
the HCT-CI scoring system was associated with
increased serious organ toxicity in our cohort. Further,
any comorbidity associated with points on the CCI was
associated with a trend toward increased serious toxic-
ity. Comorbidity captured by either the CCI or HCT-
CI was associated with prolonged LOS and total sum
of organ toxicity scores. The mPAM score was not
able to identify patients who experienced serious toxic-
ity, possibly due to the homogeneity of the cohort and
the weighting of the transplantation variables in the
mPAM scoring system.
Although comorbidity is known to be a critical
determinant of mortality after autologous HSCT
[1,2], increased comorbidity scores in patients under-
going autologous HSCT for MM was not associated
with increased mortality in the present study. But
increased toxicity was observed, which may compro-
mise performance status in this patient population.
Using the HCT-CI and CCI comorbidity assessment
systems to predict nonfatal toxicity after autologous
HSCT is a novel use of these systems.Table 4. Summary of ORs and 95% CIs after Logistic Regression Analysis
CCI Score 0
versus $1
HCT-CI Score 0
versus $1
mPAM Score # 23
versus $ 24
Toxicity grade $ 2 in 0 versus $ 1 organ 2.27 (0.99-5.22) 2.50 (1.08-5.80) 1.87 (0.82-4.30)
LOS (\18 days vs $ 19 days) 4.05 (1.76-9.29) 5.34 (2.24-12.75) 3.03 (1.35-6.77)
Total sum of toxicity grades (\2 vs $ 2 total grades) 2.19 (1.06-4.49) 2.22 (1.08-4.55) 1.93 (0.91-4.09)
1044 L. Labonte et al.To date, all of the comorbidity scoring systems
assessed in our study have been validated exclusively in
patients undergoing allogeneic HSCT, and, to the best
of our knowledge, there are no published reports on
the role of the HCT-CI in autologous HSCT popula-
tions. Overall, the risk of nonrelapse mortality is greater
in allogeneic HSCT recipients. Despite the differences
between autologous and allogeneic transplantation, our
results demonstrate that the CCI and HCT-CI indices
are useful predictors of toxicity after autologous HSCT.
One limitation of the present study is the presence
of comorbid conditions in \ 50% of patients. The
most common pretransplantation comorbidity in the
MM patients undergoing autologous HSCT was pul-
monary disease; cardiovascular conditions were less
common. Another limitation of this retrospective
analysis is that patients with advanced cardiovascular
disease and other serious comorbidities were excluded
from transplantation by the treating physicians. Fit-
ness for transplantation has been incompletely defined
but frequently involves pretransplantation evaluation
with supplementary tests, such as evaluation of left
ventricular ejection fraction, chest x-ray, pulmonary
function studies, and blood work to assess renal and
hepatic dysfunction. Significant abnormalities in any
of these tests may be sufficient grounds for exclusion
from transplantation in some centers.
We recognize that measuring toxicity after HSCT
has limitations. Although the Seattle criteria [7] have
been validated for capturing peak toxicity in both allo-
geneic and autologous HSCT, they do not necessarily
reflect global toxicity. Further, toxicity in some organ
systems may be more permanent and critical compared
with toxicity in other systems. Measures of global
toxicity, including LOS, can be affected by many issues
and are not specific. Mortality rate typically is\ 5%
after autologous HSCT in well-selected patients and
is less useful as a measure of toxicity. Likewise, transfer
to an ICU typically occurs in\ 10% of patients but
may serve as a useful indicator of toxicity. The devel-
opment of better-refined toxicity criteria that allow
more detailed assessment of organ toxicity is needed.
The present study was limited to examining the
impact of comorbidities on acute regimen-related tox-
icity. But a major concern regarding regimen-related
toxicity and acute complications of transplantation is
the risk of residual organ impairment that could ad-
versely affect quality of life in the longer term. Many
patients are concerned about the impact of aggressive
treatment on their overall functional and performance
status. Although our study provides insight into the
role of comorbid conditions and the risk of toxicity,
we cannot comment on the degree of recovery from
transplantation-related toxicity or details of their per-
formance status at posttransplantation day 100.
In conclusion, our observations suggest that for-
mal assessment of comorbidities using the HCT-CIor CCI scoring systems in patients undergoing autolo-
gous HSCT for MM may serve as a useful adjunct to
both clinical judgment and patient preference when
balancing the risk of toxicity and the benefits of trans-
plantation.
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